Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047

AIDS

Volumn 16, Issue 4, 2002, Pages 569-577

  Fichtenbaum, Carl J ^a   Gerber, John G ^a   Rosenkranz, Susan L ^a   Segal, Yoninah ^a   Aberg, Judith A ^a   Blaschke, Terrence ^a   Alston, Beverly ^a   Fang, Fang ^a   Kosel, Bradley ^a   Aweeka, Francesca ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Drug interactions; HIV infection; HMG CoA reductase inhibitors; Protease inhibitors; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY;

ADULT; ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; HEPTANOIC ACIDS; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMAN EXPERIMENTATION; HUMANS; PRAVASTATIN; PYRROLES; RITONAVIR; SAQUINAVIR; SIMVASTATIN;

EID: 0037040378     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203080-00008     Document Type: Article

References (41)

1. HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications
2. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
3. Hyperlipidemia under treatment with proteinase inhibitors
4. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort study
5. Hyperlipidemia associated with protease inhibitor therapy
6. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
7. HIV protease inhibitor induces lipodystrophy and hyperlipidemia due to the accumulation of activated sterol responsive element binding proteins in the nucleus
8. Metabolic effects of Indinavir in healthy HIV-seronegative men
9. Severe premature coronary artery disease with protease inhibitors
10. Drug treatment of lipid disorders
11. Primary prevention of coronary artery disease: Guidance from Framingham
12. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. (Adult Treatment Panel II)
13. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program
14. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials
15. Efficacy and safety of HMG-CoA reductase inhibitors (Statins) for the treatment of protease inhibitor (PI)-related hyperlipidemia: A retrospective analysis
16. Validation of a dyslipidemia algorithm in HIV-positive patients
17. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
18. Dietary advice with and without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy
19. In vitro comparative inhibition profiles of major human drug metabolizing cytochrome P450 isozymes (CYP2C9, CYP2D6, and CYP3A4) by HMG-CoA reductase inhibitors
20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
21. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
22. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
23. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s
24. The interaction of fluvastatin and cyclosporin A in renal transplant patients
25. Plasma concentration profiles of simvastatin 3-hydroxy-3=methyl-glytraryl-coenzyme A reductase inhibitor activity in kidney transplant recipients with and without ciclosporin
26. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy
27. Rhabdomyolysis after taking atorvastatin with gemfibrozil
28. Rhabdomyolysis due to interaction of simvastatin with mibefradil
29. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone
30. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
31. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals
32. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
33. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS
34. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation productrs in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry
35. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir, and indinavir
36. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin in comparison with pravastatin
37. Biotransformation of pravastatin sodium in humans
38. RhabdomyoLysls in a patient receiving simvastatin concurrently with highly active antiretroviral therapy
39. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetics (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA)
40. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin